Skip to content

Why Subscribe
About Us
Accreditation
Library
Live Events
Sign Up / Login

Why Subscribe
About Us
Accreditation
Library
Live Events
Sign Up / Login

Library

Speciality

Author / Speaker

Title of Presentation

Type of Media

Event

2024 Event

Clear

Displaying 1,101 - 1,125 of 2,711

«
1
…
43
44
45
46
47
…
109
»

Immunotherapy & targeted Therapy in Melanoma

Immunotherapy & targeted Therapy in Melanoma

By: Sanjiv Agarwala, MD

Immunotherapy & targeted Therapy in Melanoma

Immunotherapy & targeted Therapy in Melanoma

By: Sanjiv Agarwala, MD

Melanoma: Novel Advances in Immunotherapy

Melanoma: Novel Advances in Immunotherapy

By: Sanjiv Agarwala, MD, FASCO

Melanoma: Novel Advances in Immunotherapy

Melanoma: Novel Advances in Immunotherapy

By: Sanjiv Agarwala, MD, FASCO

Immunotherapy Session

Immunotherapy Session

By: Sanjiv Agarwala, MD; Pedro Barata, MD; Ahmed Zakari, MD; Pedro G. Solivan, MD

Promising Immunotherapy for Melanoma

Promising Immunotherapy for Melanoma

By: Sanjiv S. Agarwala, MD

Immunotherapy & Targeted Therapy in Melanoma

Immunotherapy & Targeted Therapy in Melanoma

By: Sanjiv S. Agarwala, MD

Immunotherapy and Targeted Therapy in Melanoma

Immunotherapy and Targeted Therapy in Melanoma

By: Sanjiv S. Agarwala, MD

Immunotherapy & Targeted Therapy in Melanoma

Immunotherapy & Targeted Therapy in Melanoma

By: Sanjiv S. Agarwala, MD

Promising Immunotherapy for Melanoma

Promising Immunotherapy for Melanoma

By: Sanjiv S. Agarwala, MD

Targeted Therapies in Cancer: Is Targeting the Same Mutation Relevant Across Histology and Tumor Type?

Targeted Therapies in Cancer: Is Targeting the Same Mutation Relevant Across Histology and Tumor Type?

By: Shivaani Kummar (OHSU)

Progress in CAR-T Cell Therapies

Progress in CAR-T Cell Therapies

By: Stephen Forman, MD

Progress in CAR-T Cell Therapies

Progress in CAR-T Cell Therapies

By: Stephen J. Forman, MD

Role of Interleukins in TIME to Improve Immunotherapy Efficacy

Role of Interleukins in TIME to Improve Immunotherapy Efficacy

By: Suresh Ramalingam, MD

Role of Interleukins in TIME to Improve Immunotherapy Efficacy

Role of Interleukins in TIME to Improve Immunotherapy Efficacy

By: Suresh Ramalingam, MD

Upfront Treatment for Common Ovarian Cancer (High Grade Serous) Versus Rare Histologies-- Focus on PARPi and Other Targeted Therapies

Upfront Treatment for Common Ovarian Cancer (High Grade Serous) Versus Rare Histologies-- Focus on PARPi and Other Targeted Therapies

By: Tara Castellano, MD

Upfront Treatment for Common Ovarian Cancer (High Grade Serous) Versus Rare Histologies-- Focus on PARPi and Other Targeted Therapies

Upfront Treatment for Common Ovarian Cancer (High Grade Serous) Versus Rare Histologies-- Focus on PARPi and Other Targeted Therapies

By: Tara Castellano, MD

Immunotherapy Updates in Melanoma

Immunotherapy Updates in Melanoma

By: Thach-Giao Truong, MD

Immunotherapy in Gynecologic Malignancies

Immunotherapy in Gynecologic Malignancies

By: Thomas Herzog, MD

Immunotherapy in Gynecologic Malignancies

Immunotherapy in Gynecologic Malignancies

By: Thomas Herzog, MD

Immunotherapy and Other Systemic Therapy in Gynecologic Malignancies

Immunotherapy and Other Systemic Therapy in Gynecologic Malignancies

By: Thomas Herzog, MD

Immunotherapy and Other Systemic Therapy in Gynecologic Malignancies

Immunotherapy and Other Systemic Therapy in Gynecologic Malignancies

By: Thomas Herzog, MD

What Comes After Immunotherapy Failure in Terms of More Immunomodulation (Anti-Angiogenic Agents, IL-15, OX-40 and Others)?

What Comes After Immunotherapy Failure in Terms of More Immunomodulation (Anti-Angiogenic Agents, IL-15, OX-40 and Others)?

By: Ticiana Leal, MD

What Comes After Immunotherapy Failure in Terms of More Immunomodulation (Anti-Angiogenic Agents, IL-15, OX-40 and Others)?

What Comes After Immunotherapy Failure in Terms of More Immunomodulation (Anti-Angiogenic Agents, IL-15, OX-40 and Others)?

By: Ticiana Leal, MD

Outside the box applications of Cryoablation

Outside the box applications of Cryoablation

By: Afshin Gangi, MD

«
1
…
43
44
45
46
47
…
109
»

© 2024 MEC Inc. All rights reserved | Digital Marketing by Katapult Marketing

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok